Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Varga, Zsuzsanna ^a   Sinn, Peter ^b   Fritzsche, Florian ^c   von Hochstetter, Arthur ^c   Noske, Aurelia ^a   Schraml, Peter ^a   Tausch, Christoph ^d   Trojan, Andreas ^d   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Pathology Institute Enge   (Switzerland)

^d Breast Cancer Center Seefeld   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; YOUNG ADULT;

EID: 84874741005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058483     Document Type: Article

References (41)

1. Mehta R, Jain RK, Badve S, (2011) Personalized medicine: the road ahead. Clin Breast Cancer 11: 20-26.
2. Morris SR, Carey LA, (2007) Molecular profiling in breast cancer. Rev Endocr Metab Disord 8: 185-198.
3. Weigelt B, Reis-Filho JS, Swanton C, (2012) Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. Ann Oncol 23Suppl 10: x211-218.
4. Italiano A (2011) Prognostic or predictive? It's time to get back to definitions! J Clin Oncol 29: 4718; author reply 4718-4719.
5. Azim HA, Jr., Michiels S, Zagouri F, Delaloge S, Filipits M, et al. (2013) Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol.
6. Albain KS, Paik S, van't Veer L, (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18Suppl 3: S141-145.
7. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, et al. (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8: R25.
8. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, et al. (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116: 5161-5167.
9. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, et al. (2008) Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 148: 358-369.
10. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, et al. (2009) Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 11: 205.
11. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
12. Ross JS, (2009) Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 16: 204-215.
13. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
14. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
15. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
16. Paik S, (2011) Is gene array testing to be considered routine now? Breast 20Suppl 3: S87-91.
17. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN, (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13: 477-493.
18. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17: 6012-6020.
19. Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, et al. (2012) Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 460: 251-259.
20. Varga Z, Caduff R, Pestalozzi B, (2005) Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 446: 136-141.
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
22. Turaga K, Acs G, Laronga C, (2010) Gene expression profiling in breast cancer. Cancer Control 17: 177-182.
23. O'Connor SM, Beriwal S, Dabbs DJ, Bhargava R, (2010) Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors. Appl Immunohistochem Mol Morphol 18: 268-272.
24. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, et al. (2011) High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29: 4279-4285.
25. Geradts J, Bean SM, Bentley RC, Barry WT, (2010) The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 28: 969-977.
26. Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, et al. (2011) Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue-a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 20: 1-10.
27. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R, (2008) Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 21: 1255-1261.
28. Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, et al. (2010) Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer. J Cancer Res Clin Oncol 136: 939-944.
29. Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, et al. (2011) Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 105: 1342-1345.
30. Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B, et al. (2011) Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 19: 431-436.
31. Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, et al. (2011) Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127: 133-142.
32. Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, et al. (2012) Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX(R)) and the PAM50 Breast Cancer Intrinsic Classifier in Early-Stage Estrogen Receptor-Positive Breast Cancer. Oncologist 17: 492-498.
33. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29: 4273-4278.
34. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, et al. (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 7: e37379.
35. Lipkus IM, Vadaparampil ST, Jacobsen PB, Miree CA, (2011) Knowledge about genomic recurrence risk testing among breast cancer survivors. J Cancer Educ 26: 664-669.
36. Richman AR, Tzeng JP, Carey LA, Retel VP, Brewer NT, (2011) Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 20: 28-35.
37. Tzeng JP, Mayer D, Richman AR, Lipkus I, Han PK, et al. (2010) Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 116: 1992-2000.
38. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, et al. (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126: 797-802.
39. Albanell J, Gonzalez A, Ruiz-Borrego M, Alba E, Garcia-Saenz JA, et al. (2011) Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol.
40. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, et al. (2011) Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist 16: 1359-1366.
41. Rayhanabad JA, Difronzo LA, Haigh PI, Romero L, (2008) Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. Am Surg 74: 887-890.